Grandeur Peak Global Advisors LLC grew its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 63.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 161,010 shares of the medical instruments supplier’s stock after purchasing an additional 62,287 shares during the period. LeMaitre Vascular makes up approximately 3.8% of Grandeur Peak Global Advisors LLC’s investment portfolio, making the stock its 7th biggest position. Grandeur Peak Global Advisors LLC’s holdings in LeMaitre Vascular were worth $15,451,000 at the end of the most recent reporting period.
Other large investors have also recently made changes to their positions in the company. Sound Income Strategies LLC boosted its stake in LeMaitre Vascular by 425.6% during the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC bought a new stake in LeMaitre Vascular in the 1st quarter worth approximately $32,000. Geneos Wealth Management Inc. increased its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC purchased a new stake in shares of LeMaitre Vascular during the 2nd quarter worth approximately $47,000. Finally, Quarry LP raised its holdings in shares of LeMaitre Vascular by 267.2% during the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after acquiring an additional 529 shares in the last quarter. 84.64% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on LMAT. Zacks Research lowered shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 14th. Wall Street Zen cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Finally, Citizens Jmp boosted their target price on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Hold” and an average target price of $110.60.
LeMaitre Vascular Price Performance
NASDAQ:LMAT opened at $80.45 on Monday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of 28.23, a PEG ratio of 2.32 and a beta of 0.53. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The business has a 50 day simple moving average of $93.04 and a 200-day simple moving average of $99.41. LeMaitre Vascular, Inc. has a 1 year low of $78.27 and a 1 year high of $118.01.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The company had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. During the same period in the prior year, the firm posted $0.60 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Equities analysts forecast that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.
LeMaitre Vascular Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be given a dividend of $0.25 per share. The ex-dividend date is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a yield of 1.2%. LeMaitre Vascular’s payout ratio is 35.09%.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.
Founded in 1983 by George D.
See Also
- Five stocks we like better than LeMaitre Vascular
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report).
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
